Therapy of viral hepatitis

Digestion

Volumn 59, Issue 5, 1998, Pages 563-578

  Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Alpha interferon; Cirrhosis; Genotypes; Hepatitis B virus; Hepatitis C virus; Hepatitis D virus; Nucleoside analogues; Randomized controlled trials

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA; VIRUS RNA;

AMINOTRANSFERASE BLOOD LEVEL; CHRONIC LIVER DISEASE; DRUG WITHDRAWAL; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; JAUNDICE; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; VIRUS HEPATITIS;

ANIMALS; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS VIRUSES; HEPATITIS, VIRAL, HUMAN; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0031927053     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007532     Document Type: Review

References (136)

1. Hoofnagle JH, Di Bisceglie AM: Treatment of chronic viral hepatitis. N Engl J Med 1997;336: 347-356.
2. Alter MJ, Mast EE: The epidemiology of viral hepatitis in the United States. Gastroenterol Clin N Am 1994;23:437-455.
3. Alter MJ, Gallagher M, Morris TT, Moyer LA, Meeks EL, Krawczynski K, Kim JP, Margolis HS: Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 1997;336:741-746.
4. Rocvhling FA, Jones WF, Chau K, DuCharme L, Mimms LT, Moore B, Scheffel J, Cuthbert JA, Thiele DL: Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis. Hepatology 1997;25:478-483.
5. Lee W: Acute liver failure. N Engl J Med 1993; 329:1862-1872.
6. Lemon S. An overview of the molecular virology and pathogenesis of type A viral hepatitis; in Rizzetto M, Purcell RH, Gerin JL, Verme G (eds): Viral Hepatitis and Liver Disease. Turin, Edizioni Minerva Medica, 1997, pp 3-8.
7. Lemon SM, Thomas DL: Vaccines to prevent viral hepatitis. N Engl J Med 1997;163:197-204.
8. Crance JM, Biziagos E, Passagot J, van Cuyck-Gandré H, Deloince R: Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J Med Virol 1990;31:155-160.
9. Lam KC, Lin HJ, Lai CL, Lam SK, Kwan YL: Isoprinosine in classical acute viral hepatitis. Am J Dig Dis 1978;23:893-896.
10. Ayrosa-Galvao PA, Castro IO: The effect of 1-b-D-ribofuranosyl, 1-1,2, 4-trizaole-3-carboxamide in acute viral hepatitis. Ann NY Acad Sci 1977;284:278-283.
11. Patki SA, Gupta P: Evaluation of ribavirin in the treatment of acute hepatitis. Chemotherapy 1982;28:298-303.
12. Lau JYN, Wright TL: Molecular virology and pathogenesis of hepatitis B. Lancet 1993;342: 1335-1344.
13. Iwarson S, Norkrans G, Nordenfelt E, Hagberg R: Interferon treatment in acute hepatitis B infection with prolonged course. Scand J Infect Dis 1990;12:233-234.
14. Sánchez-Tapias JM, Mas A, Costa J, Bruguera M, Mayor A, Ballesta AM, Compernolle C, Rod(s J : Recombinant alpha-2c Interferon therapy in fulminant viral hepatitis. J Hepatol 1987;5:205-210.
15. Tassopoulos NC, Koutelou MG, Polychronaki H, Paraloglou-Ioannides M, Hadziyannis SJ: Recombinant interferon-α therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. J Viral Hepatitis 1997;4: 387-394.
16. Hoofnagle JH: Hepatitis C. The clinical spectrum of disease. Hepatology 1997;26:15S-20S.
17. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Tada M, Ito Y, Ohto M: Resolution of acute hepatitis C after therapy with natural beta Interferon. Lancet 1991;338: 914-915.
18. Alberti A, Chemello L, Belussi F, Pontisso P, Tisminetzky S, Gerotto M, Baralle F, Simmonds P: Outcome of acute hepatitis C and role of interferon alpha therapy; in Nishioka K, Suzuki H, Oda T (eds): Viral Hepatitis and Liver Disease. Tokyo, Springer, 1994, pp 604-606.
19. Viladomiu L, Genescà J, Esteban JI, Allende H, González A, López-Talavera JC, Esteban R, Guardia J: Interferon-α in acute posttransfusion hepatitis C: A randomized controlled trial. Hepatology 1992;15:767-769.
20. Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D, Colombo M: A multicenterrandomized controlled trialofrecombinant interferon-α2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
21. Hwang S-J, Lee S-D, Chang C-Y, Lu R-H, Lo K-J: A randomized controlled trial of recombinant interferon alfa 2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994;21:831-836.
22. Belle SH, Beringer KC, Detre KM: Liver transplantation in the United States: Results from the National Pitt-UNOS liver transplant registry. United Network for Organ Sharing; in Teraska PI, Crecka JM (eds): Clinical Transplants 1994. Los Angeles, UCLA Press, 1994, pp 19-35.
23. Alexander GJM, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston ALWF, Williams R: Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987;i:66-68.
24. Hoofnagle JH, Peters MG, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Jones EA: Randomized controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-1325.
25. Perrillo RP, Schiff E, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, O'Brien C Tamburro C, Jacobson IM, Sampliner R, Feit D, Lefkowitch J, Kuhns M, Meschievitz C, Sanghvi B, Albrecht J, Gibas A, and Hepatitis Interventional Therapy Group: A randomized controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
26. Lok ASF, Wu P-C, Lai C-L, Lau JYN, Leung EKY, Wong LSK, Ma OCK, Lauder IJ, Ng CPL, Chung H-T: A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102:2091-2097.
27. Di Bisceglie AM, Bergasa N, Fong T-L, Swain MG, Baker B, Korenman J, Bergasa NV, Waggoner JG, Park Y, Hoofnagle JH: A randomized controlled trial of recombinant alpha interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-1892.
28. Ruiz-Moreno M, Rua MJ, Molina J, Moraleda G, Moreno A, Garćia-Aguado J, Carreño V: Prospective, randomized controlled trial of interferon-α in children with chronic hepatitis B. Hepatology 1991;13:1035-1039.
29. Sokal EM, Conjeevaram HS, Roberts EA, Al-varez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle JH: Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial. Gastroenterology 1998;114:988-995.
30. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-323.
31. Niederau C, Goldmann G, Heintges T, Niederau CM, Mohr L, Häussinger D: Long-term follow-up of HBeAg positive patients with chronic active hepatitis after α-interferon therapy. N Engl J Med 1996;334:1422-1427.
32. Lau D T-Y, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH: Long-term follow up of patients with chronic hepatitis B treated with alpha interferon. Gastroenterology 1997;113:1660-1667.
33. Fong T-L, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH: Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993;18: 1313-1318.
34. Lok ASF, Liang RHS, Chiu EKW, Wong K-L, Chan T-K, Todd D: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study. Gastroenterology 1991;100:182-188.
35. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC: Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;ii:588-591.
36. Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Randone A, Abate ML, Manzini P, Capalbo M, Piantino P, Verme G, Bonino F: Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993;105:845-850.
37. Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, Giustina G, Lai ME, Belussi F, Busattio G, Balestrieri A, Ruol A, Alberti A: A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15:584-589.
38. Hadziyannis SJ: Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev 1995;1:7-15.
39. Lau D T-Y, Comanor L, Minor JM, Everhart JE, Wuestehube LJ, Hoofnagle JH: Statistical models for predicting a beneficial response to interferon-α in patients with chronic hepatitis B. J Viral Hepatitis 1998;5:105-114.
40. Dushieko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26: 112S-121S.
41. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y: Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116-1121.
42. Marcellin P, Boyer N, Colin JF, Martinot-Peig-noux M, Lefort V, Matherson S, Erlinger S, Benhamou J-P: Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993;34 (suppl 2):S106.
43. Wright HI, Gavaler JS, Van Thiel DH: Preliminary experience with alpha-2b interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992;53:121-124.
44. Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD: Thymosin α1 treatment of chronic hepatitis B: A multicenter randomized, placebo- controlled double-blind study (abstract). Gastroenterology 1995;108: A1127.
45. McKenzie R, Fried MW, Sallie R,Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus S, Hoofnagle JH: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333:1099-1105.
46. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, La Fond R, Yuan L, Chisari FV, Furze J, Bartholomeur R: Development of a lipopeptide based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95:341-349.
47. Shouval D, Ilan Y: Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol 1995;23:98-101.
48. Wu GY. Wu CH: Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 1992; 267:12436-12439.
49. Von Weizsäcker F, Blum HE, Wands JR: Cleavage of hepatitis B virus by three ribozymes transcribed from a single DNA template. Biochem Biophys Res Commun 1992; 189:743-748.
50. De Man RA, Heijtink RA, Niesters HGM, Schalm SW. New developments in antiviral therapy for chronic hepatitis B infection. Scand J Gastroenterol 1995;30(suppl 212):100-104.
51. Boker KH, Ringe B, Bruger M, Pichlmayr R, Manns MP: Prostaglandin E plus famciclovir. A new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994;57:1706-1708.
52. Doong S-L, Tsai C-H, Schinazi RF, Liotta DC, Cheng Y-C: Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
53. Lai C-L, Ching C-K, Tung AK-M, Li E, Young J, Hill A, Wong BC-Y, Dent J, Wu P-C: Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology 1997;25:241-244.
54. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
55. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC: Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology 1997;113: 1258-1263.
56. Lai CL, Liaw TY, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Gray DF: 12 months of lamivudine (1,000 mg od) therapy improves liver histology: Results of a placebo controlled multicentre study in Asia (abstract). J Hepatology 1997;26:79.
57. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713.
58. Tipples GA, Ma MM, Fischer KP, Bam VG, Kneteman NM, Tyrell DL: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
59. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA: Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
60. Alrabiah FA, Sacks SL: New antiherpesvirus agents: Their targets and therapeutic potential. Drugs 1996;52:17-32.
61. Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J: The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis; 1997;176: 1517-1523.
62. Hoofnagle JH: Type D (delta) hepatitis. JAMA 1989;261:1321-1325.
63. Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Arico S, Calzia R, Picciotto A, Colombo M, Popper H: Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen: an active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98:437-441.
64. Hadziyannis SJ: Use of alpha-interferon in the treatment of chronic delta hepatitis. J Hepatol 1991;13(suppl 1):S21-S26.
65. Porres JC, Carreno V, Bartholome J, Moreno A, Galiana F, Quiroga JA: Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses. J Hepatol 1989;9:338-34.
66. Rosina F, Rizzetto M: Treatment of chronic type D (delta) hepatitis with alpha interferon. Semin Liver Dis 1989;9:264-266.
67. Rosina F, Pintus C, Meschievitz C, Rizzetto M: A randomized controlled trial of a 12-month course of recombinant human interferon-α in chronic delt a (type D) hepatitis: a multicenter Italian study. Hepatology 1991;13:1052-1056.
68. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, Gibo Y, Caruso L, Scaccabarozzi S, Criscuolo D, Ryff J-C, Balestrieri A: Treatment of chronic hepatitis D with interferon alpha-2a. N Engl J Med 1994;330:88-94.
69. Battegay M, Simpson LH, Hoofnagle JH, Sallie R, Di Bisceglie AM: Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J Med Virol 1994;44:389-392.
70. Alter HJ: Descartes before the horse: I clone, therefore I am. The hepatitis C virus in current perspective. Ann Intern Med 1991;115:644-649.
71. Marion ME, Feinstone SM: Molecular virology of hepatitis C. Hepatology 1997;25:1527-1538.
72. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, Cristianini G, Dionysos Study Group: Prevalence of chronic liver disease in the general population of Northern Italy: The Dionysos Study. Hepatology 1994; 20:1442-1449.
73. Conry-Cantilena C, Van Raden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, Di Bisceglie A, Hoofnagle J, Shih JW, Kaslow R, Ness P, Alter HJ: Routes of infection, viremia and liver disease in asymptomatic individuals with hepatitis C virus infection. N Engl J Med 1996;334:1691-1696.
74. Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A: Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340: 697-698.
75. Shakil O, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawcyzynski K, Conjeevaram HS, Sallie R, Di Bisceglie AM, Melpolder JC, Hoofnagle JH: Volunteer blood donors with antibodies to hepatitis C virus: Clinical, biochemical, virological and histological features. Ann Intern Med 1995;123:330-337.
76. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CG, National Heart, Lung and Blood Institute Study Group: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911.
77. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ: Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-974.
78. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
79. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, Purcell RH: A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104.
80. Gretch D: Diagnostic tests for hepatitis C. Hepatology 1997;26:43S-47S.
81. Nolte FS, Thurmond C, Fried M: Preclinical evaluation of Amplicor hepatitis C test for detection of hepatitis C virus RNA. J Clin Microbiol 1995;33:1775-1778.
82. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986;315:1575-1578.
83. Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, Hoofnagle JH: Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-704.
84. Shindo M, Di Bisceglie AM, Hoofnagle JH: Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992;15:1013-1016.
85. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburo C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
86. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321: 1506-1510.
87. Weiland O, Schvarz R, Wejstal R, Norkrans G, Fryden A: Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. J Hepatology 1990;11: S57-S62.
88. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, Copperé H, Cales P, Couzigou P, Benhamou J-P: Recombinant human-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 1991: 13:393-397.
89. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C, Trepo C: Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101: 497-502.
90. Benelux Multicenter Trial Group: Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard vs high dose treatment monitored by biochemical and virological markers (interim analysis). Gut 1993;(suppl):S119-S120.
91. Jouët P, Roudot-Thoraval F, Dhumeaux D, Métreau J-M, Le groupe français pour l'étude du traitement des hépatities chroniques NANB/C: Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B hepatitis. Gastroenterology 1994;106:686-690.
92. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778-789.
93. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC, Multicenter Study Group: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332: 1457-1462.
94. Lee WM: Therapy of hepatitis C: interferon alfa-2a trials. Hepatology 1997;26:89S-95S.
95. National Institutes of Health Consensus Development Conference Panel: Management of hepatitis C. Hepatology 1997;26:2S-10S.
96. Sangiovanni A, Morales R, Spinzi GC, Rumi MG, Casiraghi A, Ceriani R, Colombo E, Fossati M, Prada A, Tavani E, Minoli G. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998;27:853-856.
97. Lindsay K: Therapy of chronic hepatitis C: Overview. Hepatology 1997;26:71S-77S.
98. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
99. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patietns with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875-881.
100. Camma C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P, Vaccaro A, Fabiano C, Magrin S, Di Stefano R, Bonura C, Pagliaro L, Craxi A: Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998;28:531-537.
101. Lau DT-Y, Kleiner DE, Ghany MG, Schmid P, Hoofnagle JH: Sustained virologic response to interferon alpha in chronic hepatitis C is associated with long-term and lack of hepatitic HCV RNA (abstract). Gastroenterology 1998;114:A1284.
102. Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis G L: Discrepancy between biochemical andvirological responses to interferon-α in chronic hepatitis C. Lancet 1993;342:1208-1209.
103. Lindsay KL, Mosteller M, Rizzetto M , Davis GL, Opolon P, Goldin R, Gray DF, Boehme R, Brown N: Sustained histological response is common in the absence of virologic response to interferon therapy for chronic hepatitis C (abstract). Gastroenterology 1998;114: A1291.
104. Keeffe E, Smith C, Lyche K, CIFN Study Group: Predictive value of the timing of ALT and HCV RNA reponses in defining patients who will have a virologic-sustained response after six months of interferon therapy (abstract). Gastroenterology 1998;114:A1271.
105. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Heathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J, Consensus Interferon Study Group: Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Hepatology 1997;26:747-754.
106. Farrell GC, Bacon BR, Goldin RD, Clinical Advisory Group for the Hepatitis C Comparative Study: Lymphoblastoid Interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial. Hepatology 1998;27: 1121-1127.
107. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou J-P: Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992;116:51-53.
108. Shindo M, Di Bisceglie AM, Hoofnagle JH: Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992;102:1406-1408.
109. Reichard O, Foberg U, Fydén A, Mattsson L, Norkrans G, Sönnerborg A, Wejstål R, Yun Z-B, Weiland O: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994;19:280-285.
110. Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J,Russo A, Colombo M. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996;24: 1366-1370.
111. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnú L, Casarin C, Alberti A, TriVeneto Viral Hepatitis Group: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22: 700-706.
112. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP: Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-165.
113. Lindsay KL, Davis GL, Schiff E, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, Goff JS, Everson GT, Suva M, Katkov WN, Goodman Z, Lau JYN, Maertens G, Gogate J, Sanghvi B, Albrecht J, Hepatitis Interventional Therapy Group: Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatology 1996;24: 1034-1040.
114. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26:112S-127S.
115. Nousbaum J-B, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, Collaborative Study Group: Hepatitis C virus type 1b infection in France and Italy. Ann Intern Med 1995;122: 161-168.
116. Boyer N, Marcellin P, Degott C, Saimot AG, Erlinger S, Benhamou JP, Comité des Anti-Viraux: Recombinant interferon-α for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992;165:723-726.
117. Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, Roberts J , Wilber J, Sheridan P, Urdea M: Interferon-alfa therapy for-hepatitis C virus infection after liver transplantation. Hepatology 1994;20:773-779.
118. Féray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, Reynès, Bismuth H: An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995;22:1084-1089.
119. Shimizu YK, Iwamoto A, Hijikata M, Purcell RH, Yoshikura H: Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci USA 1992;89: 5477-5481.
120. Fong T-L, Valinluck B, Govindarajan S, Charboneau F, Adkins RH,. Redeker AG: Short-term prednisone therapy affects amino-transferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994;107:196-199.
121. Sáez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreño V: High doses of recombinant α- interferon or γ-interferon for chronic hepatitis C: A randomized, controlled trial. Hepatology 1991;13:327-331.
122. Rezakovic I, Zavaglia C, Botteli R, Idéo G: A pilot study of thymosin alpha 1 therapy in chronic active hepatitis C (abstract). Hepatology 1993;18:A252.
123. Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, Merlini R, Batezzati PM, Crosignani A, Zuin M, Manenti F: Ursodiol in the long-term treatment of chronic hepatitis: A double-blind multicenter clinical trial. J Hepatol 1993;19:459-464.
124. Pappas SC, Hoofnagle JH, Young N, Straus SE, Jones EA: Treatment of chronic non-A, non-B hepatitis with acyclovir: A pilot study. J Med Virol 1985;15:19-21.
125. Reichard O, Andersson J, Schvarcz R, Weiland O: Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-1061.
126. Di Bisceglie AM, Shindo M, Fong T-L, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH: A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-654.
127. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O: Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol 1996; 25:591-598.
128. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff L, Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997;26:473-477.
129. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH: Ribavirin as therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
130. Hoofnagle JH, Lau D, Conjeevaram HC, Kleiner DE, Di Bisceglie AM: Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepatitis 1996;3:247-252.
131. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L: A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-817.
132. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A: The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol 1995;23(suppl 2):8-12.
133. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS: Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
134. Reichard O, Norkrans G, Fryden A, Braconier J-H, Sonnerborg A, Weiland O: Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C: The Swedish Study Group. Lancet 1998;351:83-87.
135. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiffman M, Zeuzem S, Craxi A, Raffanel C, Reindollar R, Rizzetto M, International Hepatitis Interventional Therapy Group: Retreatment of relapse after interferon therapy for chronic hepatitis C: an international randomized controlled trial of interferon plus ribavirin vs interferon alone (abstract). Hepatology 1997;26:247A.
136. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, Pouyet M, Trepo C: Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-504.